Pazopanib

In the US, Pazopanib (pazopanib systemic) is a member of the drug class VEGF/VEGFR inhibitors and is used to treat Renal Cell Carcinoma.

US matches:

• Pazopanib


• Pazopanib Hydrochloride

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L01XE11

CAS registry number (Chemical Abstracts Service)

0444731-52-6

Chemical Formula

C21-H23-N7-O2-S

Molecular Weight

437

Therapeutic Category

Antineoplastic agent

Chemical Names

5-({4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide (WHO)

5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzolsulfonamide (IUPAC)

Foreign Names

• Pazopanibum (Latin)
• Pazopanib (German)
• Pazopanib (French)
• Pazopanib (Spanish)

Generic Names

• GW 786034 (IS)
• UNII-7RN5DR86CK (IS)
• Pazopanib hydrochloride (OS: USAN)
• GW786034B (IS)
• UNII-33Y9ANM545 (IS)

Brand Name

• Votrient
  GlaxoSmithKline, United States

International Drug Name Search

Glossary

IUPAC	International Union of Pure and Applied Chemistry
IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name
WHO	World Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.